About Kymera Therapeutics
Kymera Therapeutics develops treatments by targeting and breaking down specific proteins that contribute to diseases, particularly cancer and immune disorders. Their main technology, the Pegasus Platform, enables them to identify these harmful proteins and create drug candidates aimed at effectively treating various conditions. Unlike many competitors, Kymera focuses on targeted protein degradation, which can lead to more precise therapies. The company's goal is to create next-generation medicines that address unmet medical needs, supported by partnerships with organizations like Sanofi to enhance their research and development efforts.
Cambridge, MassachusettsHeadquarters
2016Year Founded
$191.6MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees
Risks
Increased competition in protein degradation could impact Kymera's market share.
Regulatory scrutiny may delay clinical trials and drug approval timelines.
Dependence on key partnerships like Sanofi could affect revenue if altered.
Differentiation
Kymera's Pegasus Platform enables precise identification and degradation of disease-causing proteins.
The company focuses on targeted protein degradation, a novel approach in drug development.
Kymera's strategic partnership with Sanofi enhances its credibility and market reach.
Upsides
Kymera raised $225M and $275M in public offerings, boosting financial resources.
HSBC's investment indicates strong confidence in Kymera's business model and prospects.
Partnership with Neosphere Biotechnologies opens new therapeutic opportunities in molecular glue discovery.
Funding
Total raised$191.63 M
Latest valuation$510.00 M
StageIPO
POST IPO EQUITY
7/31/2024$225
IPO
7/31/2020$174
SERIES B
10/31/2018$65
$325.00 MSERIES A
9/30/2017$30
$150.00 M